ATE369860T1 - Verwendung von pdgf-rezeptor tyrosin kinase inhibitoren zur behandlung von diabetischer nephropathie - Google Patents
Verwendung von pdgf-rezeptor tyrosin kinase inhibitoren zur behandlung von diabetischer nephropathieInfo
- Publication number
- ATE369860T1 ATE369860T1 AT01921298T AT01921298T ATE369860T1 AT E369860 T1 ATE369860 T1 AT E369860T1 AT 01921298 T AT01921298 T AT 01921298T AT 01921298 T AT01921298 T AT 01921298T AT E369860 T1 ATE369860 T1 AT E369860T1
- Authority
- AT
- Austria
- Prior art keywords
- sub
- treatment
- tyrosine kinase
- receptor tyrosine
- diabetic nephropathy
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP00810181 | 2000-03-03 |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE369860T1 true ATE369860T1 (de) | 2007-09-15 |
Family
ID=8174580
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT01921298T ATE369860T1 (de) | 2000-03-03 | 2001-03-01 | Verwendung von pdgf-rezeptor tyrosin kinase inhibitoren zur behandlung von diabetischer nephropathie |
Country Status (11)
Country | Link |
---|---|
US (1) | US7087608B2 (de) |
EP (1) | EP1259242B1 (de) |
JP (1) | JP2003525240A (de) |
AT (1) | ATE369860T1 (de) |
AU (2) | AU2001248324B2 (de) |
CA (1) | CA2401812C (de) |
DE (1) | DE60129934T2 (de) |
ES (1) | ES2291306T3 (de) |
HK (1) | HK1052864A1 (de) |
PT (1) | PT1259242E (de) |
WO (1) | WO2001064200A2 (de) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1408978A4 (de) | 2001-06-21 | 2005-07-13 | Ariad Pharma Inc | Neue phenylamino-pyrimidine und ihre verwendungszwecke |
DE60216281T2 (de) | 2001-06-29 | 2007-07-05 | Ab Science | Die verwendung von tyrosinkinasehemmer zur behandlung von allergischen erkrankungen |
PT1401416E (pt) | 2001-06-29 | 2007-02-28 | Ab Science | Utilização de inibidores de c-kit para tratar doenças inflamatórias intestinais (dii) |
EP1401415B1 (de) | 2001-06-29 | 2006-06-21 | AB Science | Die verwendung von n-phenyl-2-pyrimidine-amine derivaten zur behandlung von entzündlichen erkrankungen |
JP2005500041A (ja) | 2001-06-29 | 2005-01-06 | アブ サイエンス | 強力で選択的かつ非毒性のc−kit阻害剤 |
BR0211948A (pt) * | 2001-08-25 | 2004-09-14 | Arakis Ltd | O uso de antraquinonas no tratamento de doenças dos rins |
US7332330B2 (en) * | 2001-09-11 | 2008-02-19 | Renamed Biologics, Inc. | Device for maintaining vascularization near an implant |
IL162838A0 (en) | 2002-01-04 | 2005-11-20 | Univ Rockefeller | Compositions and methods for prevention and treatment peptide-of amyloid- related disorders |
AU2003232115A1 (en) * | 2002-05-13 | 2003-11-11 | Beth Israel Deaconess Medical Center | Methods and compositions for the treatment of graft failure |
JP4726486B2 (ja) | 2002-08-02 | 2011-07-20 | アブ サイエンス | 2−(3−アミノアリール)アミノ−4−アリール−チアゾールおよびそれらのc−kit阻害薬としての使用法 |
US8450302B2 (en) | 2002-08-02 | 2013-05-28 | Ab Science | 2-(3-aminoaryl) amino-4-aryl-thiazoles and their use as c-kit inhibitors |
GB0222514D0 (en) | 2002-09-27 | 2002-11-06 | Novartis Ag | Organic compounds |
WO2004105763A2 (en) | 2003-05-27 | 2004-12-09 | Haegerkvist Robert Per | Use of tyrosine kinase inhibitor to treat diabetes |
ATE395052T1 (de) * | 2003-08-15 | 2008-05-15 | Ab Science | Verwendung von c-kit-inhibitoren für die behandlung von typ-2-diabetes |
MXPA06005518A (es) | 2003-11-17 | 2006-08-17 | Novartis Ag | Uso de inhibidores de la dipeptidil peptidasa iv. |
US9073997B2 (en) | 2007-02-02 | 2015-07-07 | Vegenics Pty Limited | Growth factor antagonists for organ transplant alloimmunity and arteriosclerosis |
US9273077B2 (en) | 2008-05-21 | 2016-03-01 | Ariad Pharmaceuticals, Inc. | Phosphorus derivatives as kinase inhibitors |
SI2300013T1 (en) | 2008-05-21 | 2018-03-30 | Adriad Pharmacaceuticals, Inc. | Phosphorus derivatives as kinase inhibitors |
WO2011016861A2 (en) | 2009-08-05 | 2011-02-10 | Intra-Cellular Therapies, Inc. | Novel regulatory proteins and inhibitors |
EP2704572B1 (de) | 2011-05-04 | 2015-12-30 | Ariad Pharmaceuticals, Inc. | Verfahren zur hemmung der zellproliferation bei efgr-vermitteltem krebs |
US20150166591A1 (en) | 2012-05-05 | 2015-06-18 | Ariad Pharmaceuticals, Inc. | Methods and compositions for raf kinase mediated diseases |
US9611283B1 (en) | 2013-04-10 | 2017-04-04 | Ariad Pharmaceuticals, Inc. | Methods for inhibiting cell proliferation in ALK-driven cancers |
CN107573322A (zh) * | 2017-09-06 | 2018-01-12 | 南京优科生物医药研究有限公司 | 伊马替尼双氮氧化物、其制备方法和用途 |
AU2020242287A1 (en) | 2019-03-21 | 2021-09-02 | INSERM (Institut National de la Santé et de la Recherche Médicale) | A Dbait molecule in combination with kinase inhibitor for the treatment of cancer |
WO2020245208A1 (en) | 2019-06-04 | 2020-12-10 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of cd9 as a biomarker and as a biotarget in glomerulonephritis or glomerulosclerosis |
CN114761006A (zh) | 2019-11-08 | 2022-07-15 | Inserm(法国国家健康医学研究院) | 对激酶抑制剂产生耐药性的癌症的治疗方法 |
WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5093330A (en) * | 1987-06-15 | 1992-03-03 | Ciba-Geigy Corporation | Staurosporine derivatives substituted at methylamino nitrogen |
JP2602735B2 (ja) * | 1989-09-27 | 1997-04-23 | 株式会社大塚製薬工場 | 抗活性酸素剤 |
TW225528B (de) | 1992-04-03 | 1994-06-21 | Ciba Geigy Ag | |
JP3810020B2 (ja) | 1993-04-22 | 2006-08-16 | 武田薬品工業株式会社 | 腎疾患の予防または治療剤 |
US5795910A (en) | 1994-10-28 | 1998-08-18 | Cor Therapeutics, Inc. | Method and compositions for inhibiting protein kinases |
US5721277A (en) | 1995-04-21 | 1998-02-24 | Sugen, Inc. | Compounds and methods for inhibiting hyper-proliferative cell growth |
CA2214393A1 (en) | 1996-09-02 | 1998-03-02 | Takeda Chemical Industries, Ltd. | Tricyclic compounds, their production and use |
JPH10182644A (ja) * | 1996-11-01 | 1998-07-07 | Takeda Chem Ind Ltd | 三環性化合物、その製造法及び剤 |
CO4950519A1 (es) | 1997-02-13 | 2000-09-01 | Novartis Ag | Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion |
CO4940418A1 (es) | 1997-07-18 | 2000-07-24 | Novartis Ag | Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso |
GB9809869D0 (en) | 1998-05-09 | 1998-07-08 | Medical Res Council | Inhibition of protein kinases |
ATE371453T1 (de) | 1998-08-13 | 2007-09-15 | Novartis Pharma Gmbh | Verfahren zur behandlung von okularen neovaskularen erkrankungen |
-
2001
- 2001-01-03 US US10/220,214 patent/US7087608B2/en not_active Expired - Fee Related
- 2001-03-01 ES ES01921298T patent/ES2291306T3/es not_active Expired - Lifetime
- 2001-03-01 WO PCT/EP2001/002340 patent/WO2001064200A2/en active IP Right Grant
- 2001-03-01 AT AT01921298T patent/ATE369860T1/de active
- 2001-03-01 JP JP2001563097A patent/JP2003525240A/ja not_active Ceased
- 2001-03-01 CA CA002401812A patent/CA2401812C/en not_active Expired - Fee Related
- 2001-03-01 DE DE60129934T patent/DE60129934T2/de not_active Expired - Lifetime
- 2001-03-01 PT PT01921298T patent/PT1259242E/pt unknown
- 2001-03-01 AU AU2001248324A patent/AU2001248324B2/en not_active Ceased
- 2001-03-01 AU AU4832401A patent/AU4832401A/xx active Pending
- 2001-03-01 EP EP01921298A patent/EP1259242B1/de not_active Expired - Lifetime
-
2003
- 2003-05-27 HK HK03103784A patent/HK1052864A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
AU2001248324B2 (en) | 2005-09-15 |
HK1052864A1 (en) | 2003-10-03 |
CA2401812A1 (en) | 2001-09-07 |
PT1259242E (pt) | 2007-11-15 |
US7087608B2 (en) | 2006-08-08 |
WO2001064200A3 (en) | 2002-01-17 |
ES2291306T3 (es) | 2008-03-01 |
EP1259242B1 (de) | 2007-08-15 |
JP2003525240A (ja) | 2003-08-26 |
AU4832401A (en) | 2001-09-12 |
DE60129934D1 (de) | 2007-09-27 |
CA2401812C (en) | 2009-06-09 |
DE60129934T2 (de) | 2008-05-08 |
US20030186977A1 (en) | 2003-10-02 |
EP1259242A2 (de) | 2002-11-27 |
WO2001064200A2 (en) | 2001-09-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE369860T1 (de) | Verwendung von pdgf-rezeptor tyrosin kinase inhibitoren zur behandlung von diabetischer nephropathie | |
YU84603A (sh) | Novi inhibitori tirozin kinaze | |
DE69912581D1 (de) | Biarylessigsäure-derivate und ihre verwendung als cox-2 inhibitoren | |
EA200601830A1 (ru) | Ортозамещённые арильные или гетероарильные амидные соединения | |
TR200103352T2 (tr) | Kinas pirolotriazin inhibitörleri | |
ATE266623T1 (de) | Caspase inhibitoren und deren verwendung | |
EA200500304A1 (ru) | Производные 3-(сульфонамидоэтил)индола, предназначенные для использования в качестве миметиков глюкокортикоидов при лечении воспалительных, аллергических и пролиферативных заболеваний | |
ATE432259T1 (de) | Pyridinderivate als dipeptedyl-peptidase-hemmer | |
MXPA05010958A (es) | Derivados indazol como inhibidores jnk. | |
DK1109785T3 (da) | Indolderivater og deres anvendelse til behandling af ondartede og andre sygdomme forårsaget af patologisk celleproliferation | |
NO20062136L (no) | Imidazopyrazintyrosin-kinaseinhibitorer | |
MY146669A (en) | Pyrazole derivatives for treating hiv | |
ATE450515T1 (de) | Anilinopyrimidinderivate als ikk?inhibitoren, und hiermit in zusammenhang stehende zusammensetzungen und verfahren | |
DE602005005167D1 (de) | 1-isopropyl-2-oxo-1,2-dihydropyridin-3-carbonsäureamidderivate mit agonistischer wirkung am 5-ht4-rezeptor | |
DK1765816T3 (da) | Substituerede 1-propinylpiperaziner med affinitet for MGluR5-receptoren til behandling af smertetilstande | |
DE60206911D1 (de) | Imidazol-2-carbonsäureamid derivate als raf-kinase-inhibitoren | |
NO963706L (no) | Benzenkondenserte heterosykliske derivater og deres anvendelse | |
TR200102789T2 (tr) | Cns bozukluklarının tedavisi için 1-Arensülfonil-2-aril-pirolidin ve piperidin türevleri | |
DE60313339D1 (de) | Protein tyrosin kinase inhibitoren | |
ATE324890T1 (de) | Zusammensetzung enthaltend einen angiotensin-ii- rezeptor-antagonist und einen diuretikum und deren verwendung zur behandlung von bluthochdruck | |
ATE518538T1 (de) | Verwendung von substituierten piperazin- und morpholinderivaten | |
DE602004005881D1 (de) | Substituierte pyrazinonverbindungen zur behandlung von entzündungen | |
DE60207104D1 (de) | 2-amino-4-heteroarylethyl-thiazolinderivate und ihre verwendung als hemmstoffe der induzierbaren no-synthase | |
ATE419242T1 (de) | Pyrrolidinylharnstoffderivate als angiogeneseinhibitoren | |
DE60318089D1 (de) | Protein-tyrosine-kinase-inhibitoren |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
UEP | Publication of translation of european patent specification |
Ref document number: 1259242 Country of ref document: EP |